

October 21, 1970

Dr. Philip Tannenbaum
Associate Director of Development
Smith Kline & French Laboratories
1500 Spring Garden Street
Philadelphia, Pennsylvania 19101

Dear Phil,

Thank you for the opportunity to read the data on the cis and trans forms of doxepin. I had thought there may be some distinguishing qualities which could justify our attempt at an EEG discrimination. Lacking the basis for such a distinction makes the study less interesting.

I am returning the data sheets for your files, with thanks.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt